Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Methods of the synthesis of silicon-containing nanoparticles intended for nucleic acid delivery
Recommended Use
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Part VI: The Weight-Loss Revolution Throughout the GLP-1 development story, one observation recurred with striking consistency: patients lost weight
Where there is reduced access to GLP-1 RAs, support people with type 2 diabetes to access to structured education and weight management programmes where available
US$ 27.57
US$ 27.08
US$ 24.86
US$ 24.93
US$ 21.24
US$ 24.40
US$ 22.18
US$ 29.44
US$ 24.51
US$ 28.01
US$ 25.77
